SEC Form 4 · accession 0001179110-18-002466
Syros Pharmaceuticals, Inc. · SYRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gerald E Quirk
Officer — Chief Legal Officer
Period of report
Feb 16, 2018
Accepted (ET)
Feb 21, 2018 · 4:09 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001556263
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $10.09 | Feb 16, 2018 | A | 75,000 | A | — | Feb 15, 2028 | Common Stock | 75,000 | 75,000 | D |
| Stock Option (right to buy)F2 | $13.30 | Feb 16, 2018 | A | 11,666 | A | Feb 16, 2018 | Sep 26, 2026 | Common Stock | 11,666 | 11,666 | D |
Explanation of responses
- F1This option becomes exercisable as to 25% of the shares underlying the award on February 28, 2019, with the remainder vesting in equal monthly installments of 2.0833% of the shares underlying the award at the end of each successive month thereafter.
- F2On September 27, 2016, the Reporting Person was granted an option to purchase 35,000 shares of common stock. The option vests upon the achievement of performance-based criteria as determined by the Issuer's Board of Directors. On February 16, 2018, it was determined that certain of the performance criteria were met, resulting in vesting of the option as to 11,666 shares.